Evidence supports that athletes display a differential risk for SCA/D based on age, sex, race, sport, and level of play.9,10,14–21 Incidence rates are consistently higher in male and African American athletes. Male college basketball players have the highest reported overall risk of sudden cardiac death (SCD) at 1 in 9000 per year, and male African American college athletes have a reported SCD risk of 1 in 16 000 per year.21 In addition, studies consistently report that 2 sports alone, male basketball and football, account for 50% to 61% of all identified cases of SCA/D.12,17,21 Studies with mandatory reporting systems in other active young adult populations, such as military personnel and firefighters, have demonstrated comparable rates of SCA/D as in college male athletes.22,23,28
Without a mandatory reporting system for SCA/D in athletes, cases may go undetected and current incidence estimates may not represent the true risk. In addition, current epidemiologic studies do not provide a complete understanding of the comparative risk of SCA/D in athletes versus nonathletes as the estimated incidence range of SCA/D in the general population of adolescents and young adults overlaps with the estimated incidence range of SCA/D in adolescent and young adult athletes18,24–28 (Table 1). In a prospective study monitoring SCA in U.S. high schools, student athletes were 3.6 times more likely to suffer from SCA while on school campus than nonathlete peers.18 However, this study did not account for activities off campus and did not allow an absolute risk comparison between the groups. In contrast, a recent retrospective study comparing the risk of SCD in adolescent and young adult athletes versus nonathletes from Hennepin County, Minnesota, found a higher incidence of sudden CV-related death in nonathletes.29 This study was limited by estimates of the athlete and nonathlete populations at risk and by unclear methodology to confirm if cases participated in an organized sport.
Overall, definitive evidence that U.S. athletes as a whole are at higher risk of SCA/D than the general population of similar age is lacking. This uncertainty has generated ethical concerns about limiting a screening program for unsuspected genetic and/or congenital heart disorders to only competitive athletes.29,31 However, systematic preparticipation screening is currently required by sports governing bodies for high school, college, and professional athletes in the U.S., and there is substantial evidence that some athlete groups, especially in the college age range, have higher rates of SCA/D than estimates for the general population. A standardized approach to the evaluation and reporting of SCA/D in athletes has been proposed and may lead to more precise data moving forward.32
PREVALENCE OF DISORDERS ASSOCIATED WITH SUDDEN CARDIAC DEATH
Exercise is a known trigger and can unmask occult cardiac disease to precipitate SCA/D.33 The prevalence of cardiac conditions associated with SCA/D in young athletes is approximately 0.3%.2 This estimate is supported by multiple studies using noninvasive cardiac evaluation tools to identify cardiac disorders at potential risk of SCA/D in young athletes.34–41 The most commonly reported causes of SCA/D in athletes include hypertrophic cardiomyopathy (HCM), anomalous coronary arteries, idiopathic left ventricular hypertrophy, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, myocarditis, long QT syndrome (LQTS), ventricular preexcitation/Wolff–Parkinson–White (WPW), aortic dissection, and atherosclerotic coronary artery disease (CAD).12,21,42–45 Notably, up to 44% of athletes with SCD have no structural cardiac abnormalities identified on postmortem examination.21,43–47 These cases, known as autopsy-negative sudden unexplained death, may be due to primary electrical diseases and inherited arrhythmia syndromes. Structurally normal hearts are also reported in up to 41% of active military personnel with nontraumatic sudden death22,23 (Table 2).
Hypertrophic cardiomyopathy represents 8% to 36% of cases in U.S. athletes depending on the study.12,21 Although the reported prevalence of HCM in the general adult population is 1 in 500 or possibly higher,53–55 studies in young athletes have not identified a similar prevalence. This is perhaps due to variable morphological expression of HCM during adolescence and young adulthood or functional limitations leading to self-selection out of competitive sports. Based on existing studies, the detected prevalence of HCM in a young athletic population is approximately 1 in 800 to 1 in 2600.38,41,56–59 Atherosclerotic CAD as a cause of SCA/D in athletes increases with age and is also the most common identified cause of SCD in studies of the general population under age 35.27,48–52
The lack of standardized autopsy protocols and wider expertise in forensic CV pathology presents challenges to a more precise understanding of the etiology of SCA/D in athletes. However, even with such protocols, many of these conditions remain challenging to diagnose at autopsy. Current data sets largely involve review of autopsy results that may be limited by inadequate quality or information. In cases with negative or borderline autopsy findings, postmortem genetic testing for CV conditions with known genetic mutations may provide additional insights into the causes of SCA/D.60,61
A better understanding of the prevalence and natural history of conditions leading to SCA/D in different athlete populations will help predict the frequency of screening abnormalities and the potential value of different screening modalities. In addition, although high risk features for some CV disorders have been defined, a number of detectable conditions present an uncertain risk of SCA/D in athletes. More information is needed to fully understand which conditions or subsets of conditions will most likely lead to SCA/D.
CARDIOVASCULAR SCREENING IN ATHLETES
History and physical examination has been the traditional standard for CV preparticipation screening in the U.S.1,2,62,63 The addition of a screening ECG has both potential benefits and potential risks. Regardless of the screening strategy, the optimal age and frequency to conduct CV screening in athletes is uncertain, but generally begun between the ages of 12 and 14 and repeated every 1 to 3 years. Ideally, preparticipation CV screening should take place with adequate time before the start of a sports season to perform secondary testing of screening abnormalities.
HISTORY AND PHYSICAL EXAMINATION FOR THE CARDIOVASCULAR SCREENING OF ATHLETES
Identifying athletes with potential CV symptoms (ie, exertional syncope) or a family history of juvenile/young adult SCA/D or inheritable cardiac conditions are important elements of screening. The history and physical examination is a core skill routinely practiced by medical providers and a fundamental component of the PPE. Based on existing studies, the sensitivity of history and physical examination for the detection of cardiac disorders with elevated risk for SCA/D is about 20%,59 representing a small but important group of athletes potentially identifiable by the customary screening model. A screening examination also can identify previously unrecognized hypertension in adolescent and young adult athletes, which is important in the prevention of long-term CV morbidity.64–66
Approximately 80% of athletes who suffer SCA/D have no documented warning symptoms at the time of PPE screening and may be missed by an evaluation focused primarily on signs and symptoms.47,67–69 Standardized symptom and family history questionnaires, such as the PPE Monograph and American Heart Association (AHA) questions, also demonstrate a high positive response rate in high school (15%-31%) and college (27%-37%) athletes,40,41,70–72 requiring the medical provider to understand the purpose of the questions and the requisite pursuit of additional history to determine the need for secondary testing. Variable understanding of the PPE questions and process can create wide variation in provider follow-up and limit the effectiveness of standardized history questionnaires as a screening tool.
To be effective, PPE questionnaires require an honest patient and thus may fail to elicit a positive response to symptoms that are present but not volunteered. In addition, CV symptoms may be present in athletes with occult disorders, but misinterpreted as a normal response to vigorous exertion. Some athletes also may develop symptoms subsequent to the PPE, and thus a cardiac disorder could be missed by an evaluation performed at a single time point. Part of the PPE process should include athlete and family education on CV signs and symptoms that may develop after the examination and warrant reevaluation.
Several studies indicate that the PPE is not implemented adequately or uniformly.7,73–76 This incomplete compliance and awareness of expert guidelines complicates our understanding of the potential benefit and overall feasibility of implementing systematic questionnaires as a primary screening strategy. Recent studies suggest that less than half of primary care physicians are aware of the CV screening recommendations from the AHA or the PPE Monograph.73,74 In a survey of CV screening practices at NCAA Division I universities, 92% of responding universities did not use PPE forms that fully meet the AHA recommendations for CV screening,75 and in 2014, only 43% of state high school athletic associations require forms that fully address all the PPE Monograph (fourth edition) personal and family history CV screening recommendations.76
Physical examination also presents challenges as a screening tool for the identification of CV disorders. Clinical agreement during cardiac auscultation can vary widely among medical providers, and the ability to distinguish physiologic from pathologic murmurs is difficult even among experts.77–81 In 1 pilot study evaluating auscultation clinical agreement during a preparticipation assessment of 101 consecutive athletes, 2 board-certified family physicians each identified 6 individuals requiring further investigation, but only agreed on one, demonstrating limited agreement with a kappa of 0.114 (95% CI, −0.182 to 0.411).81 Identification and clinical agreement of the physical stigmata of Marfan syndrome and related connective tissue disorders is also challenging for both primary care providers and experts.82
Despite its use and existence for more than 2 decades, the immediate and long-term outcomes of the customary PPE are largely unknown. In fact, no study to date has tested the ability of modern recommendations for CV screening by history and physical examination alone to detect CV conditions that pose potential risk of SCA/D in athletes. Current estimates of the sensitivity of the history and physical examination are extrapolated from studies that also use other screening modalities such as ECG, and thus interpretation of history or physical examination findings may be confounded when viewed in the context of a normal or abnormal ECG. Thus, the extent to which a screening evaluation using only history and physical examination can identify athletes with conditions associated with elevated risk of SCA/D is yet to be clearly established.
The potential benefit of education, continuity, and repeat assessments using a cardiac history and physical examination also requires additional investigation. Further research is needed to improve the sensitivity, specificity, positive predictive value, and reliability of screening questions and the physical examination for the identification of athletes with at risk disorders. The physician response to positive history questions remains relatively uninvestigated and nonuniform, and more research is needed to determine the clinical features and pathways for additional evaluation in athletes. Electronic PPE formats may provide a platform to better understand the current PPE process and improve question sets. Whether a PPE performs more effectively than an annual health examination with the patient's primary care physician is also unknown.
ELECTROCARDIOGRAM FOR THE CARDIOVASCULAR SCREENING OF ATHLETES
The addition of a screening ECG to the history and physical examination increases the detection of cardiac disorders potentially at risk of SCA/D in athletes.39–41,59,68,70,72,83 An estimated 60% of the disorders associated with SCA/D in young individuals may have detectable ECG abnormalities.17 In studies conducted by centers with considerable experience in ECG screening, adding an ECG demonstrates improved sensitivity compared with history and physical examination in detecting previously undiagnosed and unsuspected cardiac disorders.34–41,56,70,83,84
Electrocardiogram is an objective test, but subject to variable interpretation. The use of modern ECG interpretation guidelines that account for physiologic adaptations in athletes have reduced the false-positive burden without a demonstrable change in sensitivity.84–87 False-positive rates have declined, ranging from 2.5% to 6.6%, when ECG review is conducted by clinicians experienced in applying modern interpretation standards.40,41,70,72,83–88
An ECG deemed to be abnormal is typically an actionable finding in the screening evaluation of athletes. An abnormal ECG also may raise awareness to vague symptoms or relevant family history that previously went unreported or uninvestigated, or initiated a more in-depth assessment of questionable physical examination findings.
Electrocardiogram interpretation in athletes is challenging even when using modern criteria, and clinical agreement and reproducibility between physicians can be limited. Some studies have demonstrated that systematic evaluation of an athlete's ECG using standardized criteria improves interpretation accuracy.89,90 However, interobserver variability and the reliability of ECG standards even among experienced physicians remains a major concern.91,92 In one study, pediatric cardiologists, without use of a standardized criteria set, achieved a sensitivity of 68% and a specificity of 70% for recognition of abnormal ECG patterns that occur infrequently but may represent conditions predisposing to SCD.93
The false-positive rate for ECG screening is strongly associated with the criteria used to guide interpretation and the experience of the interpreting physician.83–87 A false-positive ECG leads to additional testing that increases the total cost and may pose other risks to the athlete depending on the nature and timing of the test. Electrocardiogram is not 100% sensitive for ECG detectable disorders (false-negatives), and the age at which some cardiac disorders manifest ECG abnormalities is variable, raising concerns about the timing of testing and requirements for repeat testing. In addition, some conditions at risk for SCA/D do not manifest ECG abnormalities and thus would not be detectable through ECG screening. Finally, like history and physical examination, some conditions, which create an increased risk for SCA/D, are sporadic and not present at the time the ECG is obtained.
Physician training and experience are linked to accurate ECG interpretation and limit the ability of many physicians to add ECG to the current screening process. In addition, technical standards need to be adhered to because use of poor quality, low-resolution ECG instruments, or improper recording techniques can also produce misleading results.94 Physician infrastructure and resources remain major obstacles to considering quality application of ECG in the CV preparticipation evaluation of athletes.95
Education in ECG interpretation is a critical step that should be accomplished before including an ECG in the athlete CV screening process. Although educational modules have been developed, the impact and effectiveness of ECG interpretation training programs requires additional study. The secondary evaluation of athletes with ECG abnormalities can vary by physician experience,72 and the recommended evaluation of specific ECG abnormalities should be more clearly defined. Finally, the extent to which technology advances and computerized ECG interpretation algorithms using modern athlete-specific standards will improve physician ECG interpretation accuracy is unknown and requires investigation.
OUTCOMES FOR EARLY DETECTION OF CARDIOVASCULAR DISEASE
Current Assessment and Knowledge Gaps
Outcome studies of CV screening in athletes are limited and present conflicting evidence regarding the potential benefit to prevent SCA/D.35,56,96 In addition, the natural history and absolute risk of conditions associated with SCA/D in athletes identified with a cardiac disorder during preparticipation screening is largely unknown with limited outcomes-based evidence.
However, CV screening is supported based on the premise that early detection of pathologic cardiac disorders is important and could make a positive difference, and disease-specific data suggest that individualized risk stratification and management lowers mortality for some conditions. For example, large cohort studies using current management strategies and therapeutic measures have demonstrated improved survival with a low HCM-related mortality in children and young adults with HCM.97,98 A prospective study from Italy found a 73% mortality reduction in athletes from early detection of HCM compared with unscreened nonathletes.56 In addition, individualized management and in-depth counseling of children diagnosed with LQTS have shown low cardiac event rates and no deaths in 2 separate cohorts of young recreational and competitive athletes.99,100 Expert consensus guidelines for risk stratification and management of asymptomatic athletes identified with WPW pattern also were developed in partnership between the Pediatric and Congenital Electrophysiology Society and the Heart Rhythm Society.101,102 In addition, the AHA and American College of Cardiology recently updated their “Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities.”103 The language and content in these guidelines affirms from cardiology experts that early detection of conditions at risk has the potential for individual benefit.103 Finally, the accurate diagnosis of an inherited cardiac condition in an individual athlete, and the appropriate guidance for participation and treatment, may benefit not only the individual athlete but also the entire family and possibly future generations through appropriate genetic testing and counseling.
The question of whether early detection provides more benefit than harm applies to CV screening by any means and the potential risks associated with the early detection and therapeutic process. The detection of a cardiac condition associated with SCA/D statistically places an athlete in a higher risk category than an athlete without a cardiac condition detected by screening. However, data to quantify and predict individual risk is limited, and the potential harms of secondary testing of screening abnormalities must be considered.
Overdiagnosis refers to a disorder detected through screening that does not lead to symptoms or a major event.104–106 The potential for overdiagnosis can be a product of any CV screening strategy (ie, history and physical examination with or without ECG), but will increase when using modalities with a higher sensitivity. The number of athletes detected with conditions at potential risk needed to identify one athlete that will go on to have SCA/D is affected by the accuracy of the screening procedures, the predicted prevalence of disorders at elevated risk, and the estimated incidence of SCA/D (Table 3). The lack of definitive outcomes data and the uncertainty surrounding overdiagnosis complicates our understanding of whether the potential benefits of adding ECG to CV screening in athletes will outweigh the potential risks.
PHYSICIAN RESOURCES AND INFRASTRUCTURE
An ECG screening program requires physicians knowledgeable in current athlete-specific ECG interpretation standards and adequate cardiology resources to guide the secondary investigation of ECG abnormalities. The absence of a physician workforce capable of accurate ECG interpretation in athletes and the secondary evaluation of ECG abnormalities is a major obstacle to wider application of ECG screening, even among U.S. universities and colleges.6,107
Sports medicine physicians conducting or considering ECG screening as a part of a PPE are strongly encouraged to establish a close and collaborative relationship with local cardiology resources as part of a CV care team approach. Some considerations when identifying appropriate cardiology resources include specialist availability with practice models that facilitate rapid turn around times; access to timely diagnostic testing; familiarity with contemporary athlete-specific ECG interpretation criteria; and a commitment to work in partnership after the establishment of an exercise or competition-limiting diagnosis. The development of regional referral centers has also been proposed to assist in ECG interpretation and the evaluation of athletes with a suspected or known CV disorder when local expertise is not available.6
Likewise, CV screening strategies using a standard history and physical examination recommended for more than 2 decades are still not uniformly implemented or practiced.73–76 Additional education and implementation strategies regarding best practices for history and physical examination need to be pursued.
Consensus standards for ECG interpretation in athletes have evolved considerably over the last decade with each revised criteria set improving specificity.84–87 Online training modules are available at no cost to physicians to foster a common understanding of modern ECG interpretation standards (http://learning.bmj.com/ECGathlete). This may serve as a starting point for physicians, although accurate ECG interpretation will be enhanced by additional clinical experience and ongoing education.
The PPE Monograph is available to guide a standardized preparticipation history and physical examination.1 Additional resources are also available to aid in Marfan Syndrome recognition and diagnosis (http://www.marfan.org/dx/home) and cardiac auscultation skills (http://www.easyauscultation.com/heart-sounds).
Moving Forward: A New Paradigm for Cardiovascular Screening in Athletes
Although knowledge gaps exist between the available evidence and the evidence needed to precisely quantify and balance the potential benefits versus the potential harms associated with different models of CV screening, the lack of definitive data should not discourage reassessment of our current practices. The ECG screening debate is often framed as a choice between universal, mandatory screening, or no screening at all.108 These polarized options provide little guidance to explore alternative strategies for the individual physician who recognizes the limitations of the current PPE model, understands that adding an ECG has both potential benefits and risks, and recognizes a lack of clear patient-oriented outcomes evidence. The primary care sports medicine physician, however, is still responsible for the CV screening of the individual athlete and in many cases may guide decision-making for at-risk populations. A new framework to guide sports medicine physicians in choosing how they perform CV screening is warranted.
This AMSSM task force, in moving forward with this position statement and new paradigm, reviewed and reflected on guiding ethical principles and core concepts as applied to evidence-based medicine. The group acknowledged 2 key ethical principles that guide medical decision-making: beneficence and nonmaleficence. Ultimately the benefit of any intervention must exceed the risks for the intervention to be ethical. In addition, although the physician functions as an educator in informing patients about benefits and risks, in the end it is the patient who assigns them weight. The task force additionally recognized that evidence-based medicine is “the conscientious, explicit and judicious use of current best evidence in making decisions about the care of the individual patient. It means integrating individual clinical expertise with the best available external clinical evidence from systematic research.”109,110 Thus, a context for clinical decision-making for CV screening must be developed that accounts for the individual skills and expertise of the physician, as well as the individual characteristics of the patient or patient population.
At this time, this task force recognizes that there is no conclusive evidence to make a universal recommendation for or against the incorporation of ECG screening during the preparticipation evaluation. However, this task force additionally recognizes that the current PPE has substantial limitations for detecting occult cardiac disorders, the ECG provides increased sensitivity for detecting some cardiac disorders, a discordance exists between the prevalence of cardiac disorders and the rate of SCA/D, and evolving data support that some athletes are at considerably higher risk of SCA/D than others. Accordingly, the cornerstone of this document's recommendations is respect for the autonomy of individual physicians to assess the current evidence, evaluate their unique clinical situation, and decide what they believe to be the best decision for their patient or patient population. In this scenario, it is understood that some physicians may decide to implement a strategy for CV screening that incorporates an ECG, whereas others may not. Any ECG screening program if implemented, however, should have a strong infrastructure, high quality control, and consider informed consent that outlines the potential benefits and risks with the athlete (and/or parent/guardian). Optimally, the decision to incorporate or exclude an ECG from the preparticipation evaluation is one of shared decision-making between a patient and a provider.
Risk, Resources, and Opinion on Early Detection
Where does the risk/benefit ratio change so that adding an ECG is beneficial to the athlete? The primary considerations to add ECG include (1) individual risk based on age, sex, race, sport, and level of play; (2) physician expertise and available cardiology resources to conduct an ECG screening program with high quality; and (3) physician assessment that the utilization of ECG for the individual athlete provides more benefit than harm (Figure 1). Recognition of the differential risk in athletes may lead to an approach that more closely reflects individualized risk. For example, a physician may not add ECG for high school female athletes but choose to use ECG screening in male, African American college basketball players. Given the uncertainty and the desire to balance potential harms with the potential benefit of early detection, differential risk, as well as the availability of cardiology resources, may have a substantial impact on the risk/benefit ratio and thus the choice of screening strategy.
In centers where ECG screening is conducted by clinicians trained in athlete ECG interpretation using modern standards and with adequate cardiology resources for secondary investigations of ECG abnormalities, ECG screening can increase detection of athletes potentially at risk for SCA/D with lower false-positive rates. However, this may not apply to sites with less experience or those without adequate cardiology infrastructure and support. A major challenge to adding ECG is improved training in athlete ECG interpretation and the presence of cardiology expertise for the secondary evaluation of ECG abnormalities.
The foundation of CV screening relies on the premise that early detection is important and prioritized. If one determines that early detection of occult cardiac disorders is of questionable benefit or outweighed by the potential risks of a particular screening strategy and lack of definitive outcomes data, then this stance argues for less screening or perhaps no screening. Some countries endorse a paradigm with no preparticipation CV screening of any sort.44,111
Weighing the Risks Versus the Benefits
All screening risks the identification of disorders that may not become symptomatic or cause significant morbidity or mortality (overdiagnosis). If the threat (or evidence) of harms from early detection with potential overdiagnosis using a specific screening strategy are large, then screening by that means should be questioned.
The use of ECG will lead to increased detection and thus potentially a greater risk for overdiagnosis, misdiagnosis, unnecessary disqualification, or even adverse events or outcomes from activity restrictions, medical management, or evaluation and/or treatment procedures. In accepting an additional test to enhance the sensitivity of the PPE, one must also accept that the test layers on additional risk of harm through a greater number of false-positives, costly secondary investigations, and the potential for unnecessary interventions including temporary sports restriction and prohibiting exercise when not indicated. This added layer of risk may be magnified as the incidence of SCA/D declines.
Identification of CV abnormalities also leads to opportunities for risk assessment and disease management. Published studies of ECG screening in relatively small U.S. athlete cohorts have not reported major adverse events/harm or death as a result of screening.34,39–41,58,70,72,83 Nonetheless, the potential risks and complications from invasive CV procedures and therapeutic interventions remain a valid concern.112,113 More outcomes data are needed to define the procedural risk in athletes with conditions detected through screening. Screening by history and physical examination alone also has potential risks, such as false-positive responses requiring unnecessary investigations, a higher false-negative rate, and perhaps false reassurance regarding cardiac safety.
The lack of clear outcomes data at this time precludes an algorithmic or universal approach to the decision of adding an ECG to preparticipation screening. In addition, although this panel strongly supports the goals of both the PPE and CV screening, in the absence of clear outcomes-based evidence, legislative mandates requiring any particular CV screening strategy as obligatory, including history and physical examination with or without ECG, are unwarranted at this time. In the context of a developing evidence base, this panel respects the autonomy of physicians to choose the best strategy for the athlete population under their care. Physicians should be guided by the previously discussed considerations and their assessment of relevant and emerging research.
Sports medicine physicians responsible for the CV care of athletes they deem high risk for SCA/D should thoughtfully consider more intensive screening strategies, such as ECG screening. Until more definitive outcomes data are available, maintaining the current standard of CV screening, without adding the ECG, is a reasonable choice for physicians caring for athletes. Some physicians, however, may favor the potential to prevent SCA/D in targeted risk groups and chose to add ECG screening in higher risk athlete populations. Some physicians interested in ECG screening may be limited by the lack of local cardiology resources and are unable to use ECG screening programs with sufficient quality control. And finally, physicians with extensive experience in ECG screening and robust cardiology resources may choose to include ECG for all of their athletes. A standardized questionnaire should be considered during the PPE and during well child care visits that serve as the PPE to guide a comprehensive cardiac symptom and family history evaluation. Additional screening with an ECG should be considered if (and only if) accurate interpretation and proper cardiology resources can be developed or are currently available.
The Essential Role of Automated External Defibrillators and Emergency Action Plans
No screening program provides absolute protection against SCA/D. A proper emergency action plan (EAP) and access to an automated external defibrillator (AED) are essential to improving outcomes from SCA in athletes.6,13,114–116 Every school, club, and organization that sponsors athletic activities should be prepared to respond to a collapsed athlete with an acute cardiac emergency. An EAP for SCA with written policies and procedures is recommended to ensure an efficient and structured response to a cardiac emergency. An EAP for SCA including access to an AED increases the likelihood of bystander cardiopulmonary resuscitation (CPR), reduces the time to defibrillation, and improves survival from SCA. Successful programs require an organized and practiced response, an established communication method to activate the emergency medical services (EMS) system, and rescuers trained and equipped to provide CPR and defibrillation.
Prompt recognition of SCA is the first step to an efficient emergency response. Resuscitation can be delayed because SCA is mistaken for a seizure or the rescuer misinterprets agonal gasping for normal breathing.13,115 Coaches, sports medicine professionals, and other anticipated first responders to SCA in an athlete must maintain a high index of suspicion for SCA in any collapsed and unresponsive athlete. Treatment of SCA involves immediate recognition and activation of the local EMS system (call 9-1-1), early CPR (starting with chest compressions), and prompt retrieval of an AED for defibrillation. Automated external defibrillators should be strategically placed within schools and sporting facilities to achieve a collapse to first shock time of <3 minutes (although immediate availability of AEDs is ideal).116,117
FUTURE RESEARCH DIRECTIONS
This panel has identified many knowledge gaps that would benefit from further investigation. However, the following research priorities are suggested:
- Higher quality data on the etiology of SCA/D in athletes to guide screening strategies. This requires standardized autopsies, wider application of postmortem genetic testing, and review of the diagnosis in cases of SCA with survival.
- The downstream impact of any screening program requires more research, a better understanding of the natural history of cardiac disorders, and more complete outcomes data. The outcomes and clinical course of athletes identified with CV disorders at risk for SCA/D should be monitored inclusive of adverse events from diagnostic or therapeutic procedures, continued participation in sports and exercise, and the occurrence of major CV events or other CV morbidity.
- Potential avenues to refine the history and physical examination as a screening tool for cardiac disorders that place an athlete at elevated risk for SCA/D remain largely unexplored. Research efforts to improve the sensitivity, specificity, and reliability of the history and physical examination are needed.
- A potential gap exists between the quality and results of ECG screening at expert centers compared with the results of screening at more novice sites with less experience. More data addressing implementation research is needed to address the potential risks and benefits of ECG screening more broadly, and the potential impact of technology advances to assist accurate ECG interpretation results.
The primary goal of CV screening in competitive athletes is to detect cardiac disorders early in their natural history to more effectively mitigate the risk of SCA/D through improved risk stratification, targeted management, and evidence–driven activity recommendations. Acknowledging the gaps and limitations of the history and physical examination, as well as those associated with the potential addition of ECG, to accomplish the goal of CV screening does not in itself endorse a particular strategy, but is fair to the current state of the science. Electrocardiogram screening does offer enhanced detection of cardiac disorders at potential risk of SCA/D but also increases the potential for false-positive results and the associated downstream consequences. In choosing a screening strategy, sports medicine physicians should consider and assess the differential risk of the athlete, the individual needs of their specific athlete population and community, their experience and available cardiology infrastructure, and their evaluation of the risks and benefits of early detection as a means of reducing CV morbidity and mortality in athletes. No screening strategy provides absolute protection from SCA/D, and, therefore, proper emergency planning and prompt availability of AEDs during training and competition are critical. Widely practiced and accepted screening standards are not perfect and should undergo continual revision as new data emerge. Accordingly, in the absence of a clear evidence-based strategy, AMSSM supports continued research in this area to validate the optimal strategies for reducing SCA/D in athletes. Finally, AMSSM respects and supports the autonomy of an individual sports medicine physician to assess the needs of their athlete population and the assets of their community to implement an appropriate screening strategy.
The authors would like to thank the AMSSM Board of Directors and the following individuals for their review of the statement before publication: Aaron Baggish, MD, Mats Borjesson, MD, PhD, Benjamin Levine, MD, Brian Hainline, MD, Richard Kovacs, MD, and Willem Meeuwisse, MD, PhD.
1. American Academy of Family Physicians, American Academy of Pediatrics, American College of Sports Medicine, American Medical Society for Sports Medicine, American Orthopaedic Society for Sports Medicine, American Osteopathic Academy of Sports Medicine. Preparticipation Physical Evaluation. 4th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2010.
2. Maron BJ, Friedman RA, Kligfield P, et al Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 years of age): a scientific statement from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2014;64:1479–1514.
3. Corrado D, Pelliccia A, Bjornstad HH, et al Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26:516–524.
4. Dvorak J, Grimm K, Schmied C, et al Development and implementation of a standardized precompetition medical assessment of international elite football players—2006 FIFA World Cup Germany. Clin J Sport Med. 2009;19:316–321.
5. Ljungqvist A, Jenoure P, Engebretsen L, et al The International Olympic Committee (IOC) Consensus Statement on periodic health evaluation of elite athletes March 2009. Br J Sports Med. 2009;43:631–643.
6. Hainline B, Drezner JA, Baggish A, et al Interassociation Consensus Statement on Cardiovascular Care of College Student-Athletes. J Am Coll Cardiol. 2016;67:2981–2995.
7. Wingfield K, Matheson GO, Meeuwisse WH. Preparticipation evaluation: an evidence-based review. Clin J Sport Med. 2004;14:109–122.
8. Maron BJ, Levine BD, Washington RL, et al Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 2: preparticipation screening for cardiovascular disease in competitive athletes: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66:2356–2361.
9. Van Camp SP, Bloor CM, Mueller FO, et al Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc. 1995;27:641–647.
10. Maron BJ, Gohman TE, Aeppli D. Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes. J Am Coll Cardiol. 1998;32:1881–1884.
11. Drezner JA, Rogers KJ, Zimmer RR, et al Use of automated external defibrillators at NCAA Division I universities. Med Sci Sports Exerc. 2005;37:1487–1492.
12. Maron BJ, Doerer JJ, Haas TS, et al Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085–1092.
13. Drezner JA, Rao AL, Heistand J, et al Effectiveness of emergency response planning for sudden cardiac arrest in United States high schools with automated external defibrillators. Circulation. 2009;120:518–525.
14. Harmon KG, Asif IM, Klossner D, et al Incidence of sudden cardiac death in national collegiate athletic association athletes. Circulation. 2011;123:1594–1600.
15. Maron BJ, Haas TS, Ahluwalia A, et al Incidence of cardiovascular sudden deaths in Minnesota high school athletes. Heart Rhythm. 2013;10:374–377.
16. Roberts WO, Stovitz SD. Incidence of sudden cardiac death in Minnesota high school athletes 1993-2012 screened with a standardized pre-participation evaluation. J Am Coll Cardiol. 2013;62:1298–1301.
17. Maron BJ, Haas TS, Murphy CJ, et al Incidence and causes of sudden death in U.S. college athletes. J Am Coll Cardiol. 2014;63:1636–1643.
18. Toresdahl BG, Rao AL, Harmon KG, et al Incidence of sudden cardiac arrest in high school student athletes on school campus. Heart Rhythm. 2014;11:1190–1194.
19. Drezner JA, Harmon KG, Marek JC. Incidence of sudden cardiac arrest in Minnesota high school student athletes: the limitations of catastrophic insurance claims. J Am Coll Cardiol. 2014;63:1455–1456.
20. Harmon KG, Asif IM, Ellenbogen R, et al The incidence of sudden cardiac arrest in United States high school athletes. Br J Sports Med. 2014;48:605.
21. Harmon KG, Asif IM, Maleszewski JJ, et al Incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: a decade in review. Circulation. 2015;132:10–19.
22. Eckart RE, Scoville SL, Campbell CL, et al Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med. 2004;141:829–834.
23. Eckart RE, Shry EA, Burke AP, et al Sudden death in young adults an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol. 2011;58:1254–1261.
24. Atkins DL, Everson-Stewart S, Sears GK, et al Epidemiology and outcomes from out-of-hospital cardiac arrest in children: the resuscitation outcomes Consortium Epistry-cardiac arrest. Circulation. 2009;119:1484–1491.
25. Chugh SS, Reinier K, Balaji S, et al Population-based analysis of sudden death in children: the Oregon Sudden Unexpected Death Study. Heart Rhythm. 2009;6:1618–1622.
26. Cooper WO, Habel LA, Sox CM, et al ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–1904.
27. Meyer L, Stubbs B, Fahrenbruch C, et al Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. Circulation. 2012;126:1363–1372.
28. Farioli A, Christophi CA, Quarta CC, et al Incidence of sudden cardiac death in a young active population. J Am Heart Assoc. 2015;4:e001818.
29. Maron BJ, Haas TS, Duncanson ER, et al Comparison of the frequency of sudden cardiovascular deaths in young competitive athletes versus nonathletes: should we really screen only athletes? Am J Cardiol. 2016;117:1339–1341.
30. Harmon KG, Drezner JA, Wilson MG, et al Incidence of sudden cardiac death in athletes: a state-of-the-art review. Br J Sports Med. 2014;48:1185–1192.
31. Maron BJ, Friedman RA, Caplan A. Ethics of preparticipation cardiovascular screening for athletes. Nat Rev Cardiol. 2015;12:375–378.
32. Solberg EE, Borjesson M, Sharma S, et al Sudden cardiac arrest in sports—need for uniform registration: a position paper from the Sport Cardiology Section of the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Prev Cardiol. 2016;23:657–667.
33. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064–1075.
34. Fuller CM, McNulty CM, Spring DA, et al Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc. 1997;29:1131–1138.
35. Corrado D, Basso C, Pavei A, et al Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA. 2006;296:1593–1601.
36. Wilson MG, Basavarajaiah S, Whyte GP, et al Efficacy of personal symptom and family history questionnaires when screening for inherited cardiac pathologies: the role of electrocardiography. Br J Sports Med. 2008;42:207–211.
37. Bessem B, Groot FP, Nieuwland W. The Lausanne recommendations: a Dutch experience. Br J Sports Med. 2009;43:708–715.
38. Hevia AC, Fernandez MM, Palacio JM, et al ECG as a part of the preparticipation screening programme: an old and still present international dilemma. Br J Sports Med. 2011;45:776–779.
39. Baggish AL, Hutter AM Jr, Wang F, et al Cardiovascular screening in college athletes with and without electrocardiography: a cross-sectional study. Ann Intern Med. 2010;152:269–275.
40. Fudge J, Harmon KG, Owens DS, et al Cardiovascular screening in adolescents and young adults: a prospective study comparing the Pre-participation Physical Evaluation Monograph 4th Edition and ECG. Br J Sports Med. 2014;48:1172–1178.
41. Drezner JA, Prutkin JM, Harmon KG, et al Cardiovascular screening in college athletes. J Am Coll Cardiol. 2015;65:2353–2355.
42. Corrado D, Basso C, Rizzoli G, et al Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003;42:1959–1963.
43. de Noronha SV, Sharma S, Papadakis M, et al Aetiology of sudden cardiac death in athletes in the United Kingdom: a pathological study. Heart. 2009;95:1409–1414.
44. Holst AG, Winkel BG, Theilade J, et al Incidence and etiology of sports-related sudden cardiac death in Denmark–implications for preparticipation screening. Heart Rhythm. 2010;7:1365–1371.
45. Suarez-Mier MP, Aguilera B, Mosquera RM, et al Pathology of sudden death during recreational sports in Spain. Forensic Sci Int. 2013;226:188–196.
46. Ullal AJ, Abdelfattah RS, Ashley EA, et al Hypertrophic cardiomyopathy as a cause of sudden cardiac death in the young: a meta-analysis. Am J Med. 2016;129:486–496.e482.
47. Finocchiaro G, Papadakis M, Robertus JL, et al Etiology of sudden death in sports: insights from a United Kingdom Regional Registry. J Am Coll Cardiol. 2016;67:2108–2115.
48. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res. 2001;50:399–408.
49. Puranik R, Chow CK, Duflou JA, et al Sudden death in the young. Heart Rhythm. 2005;2:1277–1282.
50. Papadakis M, Sharma S, Cox S, et al The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales. Europace. 2009;11:1353–1358.
51. Solberg EE, Gjertsen F, Haugstad E, et al Sudden death in sports among young adults in Norway. Eur J Cardiovasc Prev Rehabil. 2010;17:337–341.
52. Margey R, Roy A, Tobin S, et al Sudden cardiac death in 14- to 35-year olds in Ireland from 2005 to 2007: a retrospective registry. Europace. 2011;13:1411–1418.
53. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997;350:127–133.
54. Semsarian C, Ingles J, Maron MS, et al New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–1254.
55. Maron BJ, Gardin JM, Flack JM, et al Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785–789.
56. Corrado D, Basso C, Schiavon M, et al Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998;339:364–369.
57. Basavarajaiah S, Wilson M, Whyte G, et al Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol. 2008;51:1033–1039.
58. Malhotra R, West JJ, Dent J, et al Cost and yield of adding electrocardiography to history and physical in screening Division I intercollegiate athletes: a 5-year experience. Heart Rhythm. 2011;8:721–727.
59. Harmon KG, Zigman M, Drezner JA. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: a systematic review/meta-analysis. J Electrocardiol. 2015;48:329–338.
60. Tester DJ, Ackerman MJ. The role of molecular autopsy in unexplained sudden cardiac death. Curr Opin Cardiol. 2006;21:166–172.
61. Tester DJ, Medeiros-Domingo A, Will ML, et al Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc. 2012;87:524–539.
62. Maron BJ, Thompson PD, Puffer JC, et al Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation. 1996;94:850–856.
63. Maron BJ, Thompson PD, Ackerman MJ, et al Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115:1643–1655.
64. Weiner RB, Wang F, Isaacs SK, et al Blood pressure and left ventricular hypertrophy during American-style football participation. Circulation. 2013;128:524–531.
65. Stiefel EC, Field L, Replogle W, et al The prevalence of obesity and elevated blood pressure in adolescent student athletes from the state of Mississippi. Orthop J Sports Med. 2016;4:1–9.
66. Black HR, Sica D, Ferdinand K, et al Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 6: hypertension: a scientific statement from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2015;66:2393–2397.
67. Maron BJ, Shirani J, Poliac LC, et al Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996;276:199–204.
68. Alapati S, Strobel N, Hashmi S, et al Sudden unexplained cardiac arrest in apparently healthy children: a single-center experience. Pediatr Cardiol. 2013;34:639–645.
69. Sealy DP, Pekarek L, Russ D, et al Vital signs and demographics in the preparticipation sports exam: do they help us find the elusive athlete at risk for sudden cardiac death? Curr Sports Med Rep. 2010;9:338–341.
70. Price DE, McWilliams A, Asif IM, et al Electrocardiography-inclusive screening strategies for detection of cardiovascular abnormalities in high school athletes. Heart Rhythm. 2014;11:442–449.
71. Dunn TP, Pickham D, Aggarwal S, et al Limitations of current AHA guidelines and proposal of new guidelines for the preparticipation examination of athletes. Clin J Sport Med. 2015;25:472–477.
72. Drezner JA, Owens DS, Prutkin JM, et al Electrocardiographic screening in national collegiate athletic association athletes. Am J Cardiol. 2016; In press.
73. Madsen NL, Drezner JA, Salerno JC. Sudden cardiac death screening in adolescent athletes: an evaluation of compliance with national guidelines. Br J Sports Med. 2013;47:172–177.
74. Madsen NL, Drezner JA, Salerno JC. The preparticipation physical evaluation: an analysis of clinical practice. Clin J Sport Med. 2014;24:142–149.
75. Charboneau ML, Mencias T, Hoch AZ. Cardiovascular screening practices in collegiate student-athletes. PM R. 2014;6:583–586; quiz 586.
76. Caswell SV, Cortes N, Chabolla M, et al State-specific differences in school sports preparticipation physical evaluation policies. Pediatrics. 2015;135:26–32.
77. Kumar K, Thompson WR. Evaluation of cardiac auscultation skills in pediatric residents. Clin Pediatr (Phila). 2013;52:66–73.
78. Sztajzel JM, Picard-Kossovsky M, Lerch R, et al Accuracy of cardiac auscultation in the era of Doppler-echocardiography: a comparison between cardiologists and internists. Int J Cardiol. 2010;138:308–310.
79. Dhuper S, Vashist S, Shah N, et al Improvement of cardiac auscultation skills in pediatric residents with training. Clin Pediatr (Phila). 2007;46:236–240.
80. Vukanovic-Criley JM, Criley S, Warde CM, et al Competency in cardiac examination skills in medical students, trainees, physicians, and faculty: a multicenter study. Arch Intern Med. 2006;166:610–616.
81. O'Connor FG, Johnson JD, Chapin M, et al A pilot study of clinical agreement in cardiovascular preparticipation examinations: how good is the standard of care? Clin J Sport Med. 2005;15:177–179.
82. von Kodolitsch Y, De Backer J, Schuler H, et al Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. Appl Clin Genet. 2015;8:137–155.
83. Fuller C, Scott C, Hug-English C, et al Five-year experience with screening electrocardiograms in National Collegiate Athletic Association Division I athletes. Clin J Sport Med. 2016 Feb 15 [Epub ahead of print].
84. Sheikh N, Papadakis M, Ghani S, et al Comparison of electrocardiographic criteria for the detection of cardiac abnormalities in elite black and white athletes. Circulation. 2014;129:1637–1649.
85. Brosnan M, La Gerche A, Kalman J, et al The Seattle Criteria increase the specificity of preparticipation ECG screening among elite athletes. Br J Sports Med. 2014;48:1144–1150.
86. Riding NR, Sheikh N, Adamuz C, et al Comparison of three current sets of electrocardiographic interpretation criteria for use in screening athletes. Heart. 2014;101:384–390.
87. Pickham D, Zarafshar S, Sani D, et al Comparison of three ECG criteria for athlete pre-participation screening. J Electrocardiol. 2014;47:769–774.
88. Marek J, Bufalino V, Davis J, et al Feasibility and findings of large-scale electrocardiographic screening in young adults: data from 32,561 subjects. Heart Rhythm. 2011;8:1555–1559.
89. Drezner JA, Asif IM, Owens DS, et al Accuracy of ECG interpretation in competitive athletes: the impact of using standised ECG criteria. Br J Sports Med. 2012;46:335–340.
90. Exeter DJ, Elley CR, Fulcher ML, et al Standardised criteria improve accuracy of ECG interpretation in competitive athletes: a randomised controlled trial. Br J Sports Med. 2014;48:1167–1171.
91. Magee C, Kazman J, Haigney M, et al Reliability and validity of clinician ECG interpretation for athletes. Ann Noninvasive Electrocardiol. 2014;19:319–329.
92. Brosnan M, La Gerche A, Kumar S, et al Modest agreement in ECG interpretation limits the application of ECG screening in young athletes. Heart Rhythm. 2015;12:130–136.
93. Hill AC, Miyake CY, Grady S, et al Accuracy of interpretation of preparticipation screening electrocardiograms. J Pediatr. 2011;159:783–788.
94. Kligfield P, Gettes LS, Bailey JJ, et al Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2007;49:1109–1127.
95. Asplund CA, Asif IM. Cardiovascular preparticipation screening practices of college team physicians. Clin J Sport Med. 2014;24:275–279.
96. Steinvil A, Chundadze T, Zeltser D, et al Mandatory electrocardiographic screening of athletes to reduce their risk for sudden death proven fact or wishful thinking? J Am Coll Cardiol. 2011;57:1291–1296.
97. Maron BJ, Rowin EJ, Casey SA, et al Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation. 2016;133:62–73.
98. Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016;13:1155–1165.
99. Johnson JN, Ackerman MJ. Return to play? Athletes with congenital long QT syndrome. Br J Sports Med. 2013;47:28–33.
100. Aziz PF, Sweeten T, Vogel RL, et al Sports participation in genotype positive children with long QT syndrome. JACC Clin Electrophysiol. 2015;1:62–70.
101. Cohen MI, Triedman JK, Cannon BC, et al PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm. 2012;9:1006–1024.
102. Al-Khatib SM, Arshad A, Balk EM, et al Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: a systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133:e575–e586.
103. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: preamble, principles, and general considerations: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66:2343–2349.
104. Oeffinger KC, Fontham ET, Etzioni R, et al Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314:1599–1614.
105. Myers ER, Moorman P, Gierisch JM, et al Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015;314:1615–1634.
106. Keating NL, Pace LE. New guidelines for breast cancer screening in US women. JAMA. 2015;314:1569–1571.
107. Drezner JA. ECG screening in athletes: time to develop infrastructure. Heart Rhythm. 2011;8:1560–1561.
108. Drezner JA, Levine BD, Vetter VL. Reframing the debate: screening athletes to prevent sudden cardiac death. Heart Rhythm. 2013;10:454–455.
109. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268:2420–2425.
110. Sackett D. Evidence-based medicine. Lancet. 1995;346:1171.
111. Risgaard B, Tfelt-Hansen J, Winkel BG. Sports-related sudden cardiac death: how to prove an effect of preparticipation screening? Heart Rhythm. 2016;13:1560–1562.
112. Olde Nordkamp LR, Postema PG, Knops RE, et al Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm. 2016;13:443–454.
113. Hamilton RM. Implantable devices in young patients: hitting the reset button on risk versus benefit. Heart Rhythm. 2016;13:455–456.
114. Drezner JA, Courson RW, Roberts WO, et al Inter-association task force recommendations on emergency preparedness and management of sudden cardiac arrest in high school and college athletic programs: a consensus statement. Clin J Sport Med. 2007;17:87–103.
115. Drezner JA, Toresdahl BG, Rao AL, et al Outcomes from sudden cardiac arrest in US high schools: a 2-year prospective study from the National Registry for AED Use in Sports. Br J Sports Med. 2013;47:1179–1183.
116. Casa DJ, Almquist J, Anderson SA, et al The inter-association task force for preventing sudden death in secondary school athletics programs: best-practices recommendations. J Athl Train. 2013;48:546–553.
117. Dvorak J, Kramer EB, Schmied CM, et al The FIFA medical emergency bag and FIFA 11 steps to prevent sudden cardiac death: setting a global standard and promoting consistent football field emergency care. Br J Sports Med. 2013;47:1199–1202.
electrocardiogram; sudden cardiac arrest; sudden cardiac death; prevention; sports
Supplemental Digital Content
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.